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A B S T R A C T   
Nicotinamide adenine dinucleotide (NAD) is a REDOX cofactor and metabolite essential for neuronal survival. 
Glaucoma is a common neurodegenerative disease in which neuronal levels of NAD decline. We assess the effects 
of nicotinamide (a precursor to NAD) on retinal ganglion cells (the affected neuron in glaucoma) in normal 
physiological conditions and across a range of glaucoma relevant insults including mitochondrial stress and axon 
degenerative insults. We demonstrate retinal ganglion cell somal, axonal, and dendritic neuroprotection by 
nicotinamide in rodent models which represent isolated ocular hypertensive, axon degenerative, and mito-
chondrial degenerative insults. We performed metabolomics enriched for small molecular weight metabolites for 
the retina, optic nerve, and superior colliculus which demonstrates that ocular hypertension induces widespread 
metabolic disruption, including consistent changes to α-ketoglutaric acid, creatine/creatinine, homocysteine, and 
glycerophosphocholine. This metabolic disruption is prevented by nicotinamide. Nicotinamide provides further 
neuroprotective effects by increasing oxidative phosphorylation, buffering and preventing metabolic stress, and 
increasing mitochondrial size and motility whilst simultaneously dampening action potential firing frequency. 
These data support continued determination of the utility of long-term nicotinamide treatment as a neuro-
protective therapy for human glaucoma.  
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1. Background 
Glaucoma is one of the most common neurodegenerative diseases, 
and the leading cause of irreversible blindness, affecting ~80 million 
people worldwide [1]. Age, genetics, and elevated intraocular pressure 
(IOP) are major risk factors, but to date, the only clinically available 
therapies target the reduction of IOP. For the many patients which are 
refractory to IOP lowering treatments, surgical interventions are 
commonly used in order to limit the progressive neurodegeneration and 
visual impairment [2]. No therapy currently targets the neuronal pop-
ulation that degenerates in glaucoma. Ultimately, 42% of treated glau-
coma patients progress to blindness in at least one eye [3]. With an 
increasingly aged population, glaucoma will continue to be a significant 
health and economic burden and thus neuroprotective strategies tar-
geting the retina and optic nerve are of great therapeutic need. 
Retinal ganglion cells, the output neuron of the retina whose axons 
converge to form the optic nerve, display a progressive, compartmen-
talized neurodegeneration leading to the characteristic visual dysfunc-
tion seen in glaucoma. We have previously demonstrated mitochondrial 
abnormalities occurring prior to neurodegeneration in glaucoma (in 
glaucoma patients and animal models [4,5]). The latter study, utilizing 
the DBA/2J mouse model of glaucoma, has identified that nicotinamide 
adenine dinucleotide (NAD; an essential REDOX cofactor and metabo-
lite) declines in the retina in an age-dependent manner and renders 
retinal ganglion cells susceptible to IOP-related stress, driving glau-
comatous neurodegeneration. The prevention of NAD decline by dietary 
supplementation with nicotinamide (NAM; the amide form of vitamin 
B3, an NAD precursor via the NAD-salvage pathway in neurons) or by 
intravitreal viral gene-therapy overexpressing Nmnat1 (a terminal 
enzyme for NAD production) was robustly protective against retinal 
ganglion cell neurodegeneration and prevented a number of early gene 
expression changes in DBA/2J retinal ganglion cells [5]. Glaucoma pa-
tients have been demonstrated to have systemically low levels of NAM in 
sera [6] which supports a hypothesis in which pathogenically low NAD 
leads to glaucoma susceptibility. These findings have driven interest in 
nicotinamide as a treatment for glaucoma, including the planning and 
initiation of a number of clinical trials, e.g. NCT03797469 which is 
ongoing and Hui et al. (2020) which is now completed [7]. In this trial, 
as part of a multi-national collaborative team, we have demonstrated 
significant visual recovery in glaucoma patients over a 6 month treat-
ment period (cross-over design; step up 1.5 g/d to 3.0 g/d nicotinamide 
[7]). Nicotinamide’s excellent long clinical history, combined with good 
safety profile, tolerance at high doses, and affordability has facilitated 
rapid translation into initial small scale clinical trials [8,9]. However, 
translation to larger scale trials, the evaluation of earlier intervention 
protocols, and/or longer-term clinical outcomes requires a deeper un-
derstanding of the effects of nicotinamide on retinal ganglion cells under 
both neurodegenerative conditions and normal physiological states. 
This is of critical importance since disease progression is often hetero-
geneous (i.e. a mix of healthy, degenerating, and dead cells) and if 
prophylactic treatment is to be considered (which is ideal since visual 
deficits present once the degenerative processes have already been 
initiated [10]). 
We bridge the gap between the bench and bedside by demonstrating 
further evidence of neuroprotection through nicotinamide supplemen-
tation across a number of glaucoma-related retinal ganglion cell tar-
geted insults, using a number of retinal ganglion cell specific tools. We 
identify early metabolic changes in the retina in a rat model of ocular 
hypertensive glaucoma (elevated IOP), which are prevented by nico-
tinamide supplementation. Importantly, chronic dietary nicotinamide 
supplementation causes limited metabolic variation in non-diseased 
visual system tissues supporting potential prophylactic treatments. 
Nicotinamide administration also buffers retinal ganglion cell meta-
bolism, increases oxidative phosphorylation, and positively alters 
mitochondrial morphology and dynamics in retinal ganglion cells at 
doses which are neuroprotective. These data help support 
nicotinamide’s use in the clinic, and support the initiation of clinical 
trials to determine the effect of nicotinamide on longer-term disease 
progression. 
2. Materials and methods 
2.1. Animal strain and husbandry 
All breeding and experimental procedures were undertaken in 
accordance with the Association for Research for Vision and Ophthal-
mology Statement for the Use of Animals in Ophthalmic and Research. 
Individual study protocols were approved by Stockholm’s Committee for 
Ethical Animal Research (10389-2018). Animals were housed and fed in 
a 12 h light/12 h dark cycle with food and water available ad libitum. 
Adult, male Brown Norway rats (BN, aged 12–20 weeks, weighing 
300–400 g, SCANBUR) were utilized for inducing ocular hypertension 
(detailed below). C57BL/6J and MitoV (strain details and generation 
detailed below) mouse strains were bred and utilized at 12–20 weeks of 
age. For rats, Nicotinamide (NAM, PanReac AppliChem) was dissolved 
in drinking water (200 mg/kg/d, based on average consumption). 
Higher doses were achieved by combining treated drinking water and a 
custom diet (3130 ppm NAM to achieve 400 mg/kg/d, or 9380 ppm 
NAM to achieve 800 mg/kg/d based on a pre-determined g/d con-
sumption of chow, base RM3 P diet, SDS). For mice, NAM was dissolved 
in drinking water (500 mg/kg/d based on average consumption). Water 
was protected from light and changed every 3–5 days and chow was 
maintained as necessary; both were provided in sufficient quantity to be 
available ad libitum. 
2.2. Induction and monitoring of rat ocular hypertension 
Rat ocular hypertension was induced using a paramagnetic bead 
model as previously described [11]. Rats were anesthetized with an 
intraperitoneal injection of ketamine (37.5 mg/kg) and medetomidine 
hydrochloride (1.25 mg/kg). Microbeads (Dynabead Epoxy M − 450, 
Thermo Fisher) were prepared in 1x Hank’s balanced salt solution (HBSS 
-CaCl2 –MgCl2 -phenol red, Gibco) and 6–8 μl of bead solution was 
injected into the anterior chamber. Beads were directed with a magnet 
to block the iridocorneal angle. Rats received either bilateral injections 
(OHT) or remained bilateral un-operated (naïve), normotensive controls 
(NT). For rats pre-treated with NAM, NAM was given 1 week prior OHT 
induction (at either 200, 400, or 800 mg/kg/d) and maintained 
throughout the duration of the experiment. Intraocular pressure (IOP) 
was measured using a rebound tonometer (Tonolab, Icare). Rats were 
habituated to tonometry in the week prior to induction. Baseline IOP 
was recorded the morning before surgery and every 2–4 days after-
wards. Rats were awake and unrestrained for tonometry. IOP recordings 
were always performed between 9 and 10am to avoid the effects of the 
circadian rhythm on IOP. 
2.3. OCT imaging 
Optical coherence tomography (OCT) was performed at 14 days post 
IOP in BN rats, prior to euthanasia (n = 9 eyes NT, 7 OHT, 8 OHT treated 
with 200 mg/kg/d NAM (OHT-NAM)). Pupils were dilated with topical 
Phenylephrine Hydrochloride (2.5% w/v) eye drops before anesthesia 
was induced with an intraperitoneal injection of ketamine and mede-
tomidine hydrochloride as above. OCT imaging was performed using a 
Phoenix Micron IV (Phoenix) with image-guided OCT attachment. B- 
scans centered on the ONH were captured in the horizontal and vertical 
plane. Image analysis was performed in MATLAB (MATrix LABoratory). 
First the retinal pigment epithelium and internal limiting membrane 
were delineated manually. In the presence of cupping, the cup depth was 
measured automatically as the vertical distance between the cup base 
and midpoint of the neuroretinal peaks. This measurement was used to 
determine loss of neuroretinal rim. 
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2.4. Retina axotomy explant model 
A retinal axotomy model was established with modification form 
previously described protocols [12,13]. Mice were euthanized by cer-
vical dislocation and eyes immediately enucleated. Retinas were 
dissected free in cold HBSS and flat mounted on cell culture inserts 
(Millicell 0.4 μm pore; Merck) ganglion cell layer up. Retinas were 
maintained in culture (37 ◦C, 5% CO2) fed by Neurobasal-A media 
supplemented with 2 mM L-glutamate (GlutaMAX), 2% B27, 1% N2, and 
1% penicillin/streptomycin (all Gibco) in 6-well culture plates. Half the 
media volume was changed after 2 days. For NAM treated retinas, NAM 
was dissolved in the culture media to a concentration of 100 mM or 500 
mM. Retinas were removed from culture for further processing after 12 
h, 1 day, 3 days or 5 days ex vivo (DEV). 
2.5. Intravitreal rotenone model 
Rotenone toxicity induced degeneration was induced in the retina 
following established protocols [14,15]. Mice were anesthetized with an 
intraperitoneal injection of ketamine (37.5 mg/kg) and medetomidine 
hydrochloride (1.25 mg/kg). Bilateral intravitreal injections were per-
formed using a 33G tri-beveled needle on a 10 μl glass syringe (WPI). 
One μl of a 10 mM rotenone (MP Biochemicals) solution dissolved in 
DMSO (PanReac AppliChem) or DMSO only (vehicle only control) was 
injected into the vitreous and the needle maintained in place for 30 s for 
distribution. For NAM pre-treated retinas, NAM (500 mg/kg/d) was 
administered in drinking water 1 week prior to rotenone injection. Mice 
were euthanized 24 h after injection by cervical dislocation and eyes 
immediately enucleated for further processing. 
2.6. Cryo-sectioning 
Rats were heavily anesthetized by intraperitoneal injection of 
pentobarbital (75 mg/kg) and euthanized by cervical dislocation. Mice 
were euthanized by cervical dislocation. Eyes for cryo-sectioning were 
enucleated and fixed by immersion in 4.7% PFA for 24 h. The tissue was 
cryo-protected by immersion in 30% sucrose for 24 h before freezing in 
optimal cutting temperature medium (Sakura) on dry ice. Blocks were 
maintained at − 80 ◦C until use. 20 μm cryo-sections were cut (anterior 
to dorsal plane) using a cryostat (Cryostar NX70, Thermo Scientific) and 
stored at − 20 ◦C. 
2.7. Immunofluorescent labelling 
Immunofluorescent labelling followed a standard protocol for cryo- 
sections and flat mount retina with the following exceptions. Cryo- 
sections were air dried for 15 min and rehydrated in 1 M PBS for 5 
min before following the protocol. Antibodies are detailed in Supple-
mentary Table 1. For the standard protocol, tissue was isolated using a 
hydrophobic barrier pen (VWR), permeabilized with 0.5% Triton X-100 
(VWR) in 1 M PBS for 30 min, blocked in 5% bovine serum albumin 
(Fisher Scientific) in 1 M PBS for 30 min, and primary antibody applied 
and maintained overnight at 4 ◦C. 5 × 5 min washes in 1 M PBS were 
performed before applying secondary antibodies and maintaining at 
room temperature for 2 h. Tissue was washed as before and DAPI nu-
clear stain (1 μg/ml in 1 M PBS) was applied for 10 min. Tissue was then 
washed once in PBS before mounted using Fluoromount-G and glass 
coverslips (Invitrogen). Slides were sealed with nail-varnish. 
2.8. Analysis of RGC somal death and degeneration 
RGC loss and nuclear shrinkage was assessed through RBPMS and 
DAPI labelling of flat mounts. Images were acquired on a Zeiss Axioskop 
2 plus epifluorescence microscope (Karl Zeiss). Six images per retina 
(40X magnification, 0.25 μm/pixel) were taken equidistant at 0, 2, 4, 6, 
8, and 10 o’clock about a superior to inferior line through the optic 
nerve head (~1000 μm eccentricity). Images were cropped to 150 μm2 
and RBPMS + cells and DAPI nuclei counted using the cell counter 
plugin for Fiji ([16]; only round nuclei were counted, thus excluding 
vascular endothelium); counts were expressed as a density per 0.01 
mm2, averaged across the 6 images. For measurement of nuclear 
diameter, 30 nuclei (from RBPMS + cells; or as many surviving cells as 
were able to be measured) per cropped image were measured using the 
line tool, giving an average diameter; this was averaged across the 6 
images to produce a final average diameter per retina. These analyses 
were performed on rat retina (n = 10 eyes from NT, 10 eyes from OHT, 9 
eyes from OHT-NAM [200 mg/kg/d], 12 eyes from OHT-NAM [400 
mg/kg/d], 12 eyes from OHT-NAM [800 mg/kg/d]), C57BL/6J mouse 
retina from retinal explants (n = 6 eyes for all groups: 0 days ex vivo 
(DEV; control), 0.5 DEV, 1 DEV, 3 DEV, 5 DEV, 3 DEV +NAM [100 mM], 
3 DEV + NAM [500 mM]), C57BL/6J mouse retina from intravitreal 
rotenone injection (n = 8 eyes from DMSO control, 8 eyes from rotenone 
injected, 8 eyes from rotenone + NAM [500 mg/kg/d]). 
2.9. Analysis of RGC axonal degeneration 
Axon integrity in the nerve fiber layer (NFL) of retina following 
axotomy explant was assessed relative to control (n = 6 eyes for all 
groups: 0 days ex vivo (DEV; control), 3 DEV, 3 DEV + NAM [100 mM], 3 
DEV + NAM [500 mM]). Images of β-tubulin labelled axons adjacent to 
the optic nerve head were acquired on a Zeiss Axioskop 2 plus epi-
fluorescence microscope, cropped to 250 × 50 μm size and the size and 
number of varicosities measured. Images were converted to 8 bit, 
thresholded (200–255) and binarised. Varicosities were analyzed using 
the ImageJ particle analyzer (Fiji; 1–10 μm size filter to remove single 
pixel and long, thin axon segments [17]). The number of particles/mm2 
and the average size of particles (μm2) were taken as varicosity density 
and size. 
2.10. Analysis of RGC dendritic degeneration 
Dendritic degeneration was assessed in axotomy explant retina 
through DiOlistic labelling of individual RGC dendritic arbors (using a 
Helios gene gun system, Biorad, as previously described [18]). Bullets 
were prepared at a ratio of 2 mg DiI, 4 mg of DiO, and 80 mg Tungsten 
(1.7 μm diameter) to 30.5 cm of Tezfel tubing (Biorad), by dissolving the 
dyes in 400 μl of methylene chloride and applying over the tungsten to 
air dry. The coted tungsten was collected and transferred into the tubing, 
and distributed along the length of the tubing by vortexing. Individual 
bullets were cut to 1.2 cm C57BL/6J mouse retinas were subject to 
axotomy explant (n = 10 eyes for 0 days ex vivo (DEV; control), 12 eyes 
for all 3 DEV groups: 3 DEV, 3 DEV + NAM [100 mM], 3 DEV + NAM 
[500 mM]) and labelled ballistically. For 0 DEV, retinas were dissected 
in HBSS and immediately labelled, for 3 DEV groups retinas were 
removed from culture and labelled. For labelling, retinas were flat 
mounted on to glass slides, all liquid was removed, a culture insert was 
inverted over the retina to act as a filter to large particle clumps, and the 
contents of a single bullet discharged at a gene gun pressure of 120 psi. 
Tissue was transferred to a culture dish containing Neurobasal-A media 
(supplemented as in the retina axotomy explant model above) and 
maintained at 37 ◦C, 5% CO2 for 30 min. Retinas were then fixed in 4% 
PFA for 1 h, washed in 1 M PBS, nuclei labelled with Hoechst (Invi-
trogen) for 15 min, washed again and mounted with FluorSave reagent 
(Merck). After drying, coverslips were sealed. Images of individual RGC 
dendritic arbors were acquired on a Leica SP8 confocal microscope 
(Leica Systems; 20X magnification, 0.45 μm/pixel, 1 μm z-thickness). 
Whole dendritic arbors were reconstructed using Imaris (version 9.3.1, 
Bitplane) where individual RGC dendritic fields were manually selected 
as areas of interest (used to calculate dendritic field areas) and dendrites 
automatically traced using the filaments tool. Total dendritic length was 
calculated and Sholl analysis performed (dendritic intersections per 
binned distance from the soma center, 10 μm steps) and area under the 
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curve (AUC) of the Sholl curve was calculated. Dendritic health and 
integrity was evaluated by quantifying dendrite varicosities. Varicosities 
were identified automatically by the spot tool and a density per cell 
calculated by normalizing to total dendritic length and dendritic field 
area. 
2.11. Mitochondrial RNA to nuclear RNA ratio 
The ratio of RNA from genes encoded in the mitochondrial (mt) and 
nuclear (nu) genome can differential expression of mitochondrial genes 
or loss/gain of mitochondrial numbers [19]. Six C57BL/6J mouse retina 
following 3 days ex vivo of the retina axotomy explant model, and six 
0 DEV controls were homogenized into 400 μl buffer RLT (Qiagen) with 
1% β-mercaptoethanol (Fisher Scientific) using a QIAshredder kit 
(Qiagen) according to the manufacturer’s instructions. RNA was 
extracted using RNeasy Mini Kits (Qiagen) according to the manufac-
turer’s instructions. RNA was extracted into nuclease-free water, and 
RNA concentration was measured in a 1 μl sample diluted 1:200 in 
nuclease-free water in a spectrophotometer (BioPhotometer, Eppen-
dorf). cDNA was synthesized using 1 μg of input RNA with an iScript™ 
cDNA Synthesis Kit and MyIQ thermocycler (both Bio-Rad) and stored at 
− 20 ◦C overnight. RT-qPCR was performed using 1 μg of input cDNA, 
7.5 μl of SsoAdvanced Universal SYBR Green Supermix and 1 μl of the 
following DNA templates (Prime PCR Assay, Bio-Rad): mt-Co2 (mito-
chondrial; mus musculus), Rps18 (nuclear; mus musculus), and Tbp 
(housekeeping; mus musculus). A MyIQ thermocycler was used with a 3 
min activation and denaturation step at 95 ◦C, followed by an amplifi-
cation stage comprising 50 cycles of a 15 s denaturation at 95 ◦C and 1 
min annealing and plate read at 60 ◦C. Analysis was performed ac-
cording to the ΔΔCT method outlined by Quiros et al. [19] giving a 
mtRNA:nuRNA ratio. ΔΔCTs were compared by student’s t-test. 
2.12. Metabolomics 
BN rats were induced with OHT for 3 days or remained as NT con-
trols (as described above). Rats were either pretreated with NAM (800 
mg/kg/d) for 7 days (10 days total exposure) or were untreated (n = 8 
eyes NT, n = 8 eyes OHT, n = 8 eyes NT-NAM, n = 8 eyes OHT-NAM). 
Rats were euthanized by pentobarbital injection and cervical dislocation 
(as described above). Retinas were immediately dissected on ice cold 
HBSS (optic nerve head was not included), wiped dry and weighed 
before snap freezing on dry ice. A second investigator removed the brain 
and attached optic nerves immediately after death. Optic nerves were 
separated at the chiasm and weighed before freezing as for retinas. The 
superior colliculus (SC) was isolated and separated into left and right 
hemispheres before weighing and freezing as for the retina. Tissue was 
stored on dry ice and shipped to the Swedish Metabolomics Centre for 
sample processing. 200 μl of 90:10 MeOH:H2O was added to each frozen 
sample on dry ice, acid washed glass-beads (425–600 μm; Sigma 
Aldrich) were added to constitute 50% v/v of the MeOH:H2O solution 
and tissues were disrupted by shaking at 30 Hz for 3 min, followed by an 
additional shaking step after the addition of 100 μl of H2O. Samples were 
then centrifuged (14,000 RPM, 10 min, 4 ◦C) and 100 μl of the super-
natant was transferred to HPLC vials and immediately analyzed. 2 μl was 
injected into an Agilent 1290 UPLC-system connected to an Agilent 6550 
Q-TOF mass spectrometer with an Agilent Jet Stream electrospray 
ionization (ESI) source. Data was collected in positive and negative 
ionization mode. The HPLC column used was an HILIC (iHILIC-Fusion 
(+), 100 × 2.1 mm, 3.5 μM, 100 Å, Hilicon AB). HILIC elution solvents 
used were A) 50 mM ammonium formate in H2O and B) 90:10 Aceto-
nitrile:[50 mM ammonium formate in H2O]. Chromatographic separa-
tion at a flow rate 0.4 mL/min was achieved using the following linear 
gradient: min 0 = 90% B, min 4 = 85% B, min 5 = 70% B, min 7 = 55% 
B, min 10 = 20% B, min 10.01 = 90% B, min 15 = 90% B. Seventy three 
low molecular weight metabolites that could be verified with standards 
were detected. Metabolites were quantified as area under the curve of 
the mass spectrometry peak and normalized to an internal standard for 
negative and positive runs, then normalized to tissue weight. Data were 
analyzed using MetaboAnalyst (version 4.0 [20,21]). Groups were 
compared by two-sample t-tests with an adjusted P value (false discov-
ery rate, FDR) cutoff of 0.05 deemed significant. Dendograms were 
created using hierarchical clustering (HC) in R (1-cor, Spearman’s rho). 
Heatmaps were created in R and using Morpheus (https://software.br 
oadinstitute.org/morpheus). Principle component analysis was calcu-
lated using Pareto scaling to reduce the effect of magnitude [22], 
without excluding this dimension entirely. Pathways analysis was per-
formed in MetaboAnalyst using the Rattus norvegicus KEGG library. 
Circos plots were created in R using the circlize package [23], using 
Spearman’s rank correlations with a P value adjusted for multiple 
comparisons. 
2.13. Luminometry-based NAD assays 
To measure NAD concentration in retina and optic nerves following 
14 days of OHT, BN rats were anesthetized by intraperitoneal injection 
of pentobarbital (75 mg/kg), and euthanized by cervical dislocation (n 
= 6 eyes and optic nerves from NT, 6 eyes and optic nerves from OHT). 
Whole eyes were removed and retina dissected in HBSS as described 
above. The brain was removed with attached optic nerves. Optic nerves 
were cut at the chiasm and 4 mm from the end proximal to the eye was 
measured and collected and stored at 4 ◦C in HBSS until further pro-
cessing. Retinas were transferred to 500 μl of dispase (5000 U, Corning) 
and put on a heating block (Thermomixer C, Eppendorf) at 37 ◦C, 350 
rpm for 30 min before dissociation by gentle trituration. Cell concen-
tration was determined by cell counting on a hemocytometer (C-Chip, 
NanoEntek) and each sample was diluted to a concentration of 2 million 
cells/ml. Retina and optic nerve samples were then homogenized for 20 
s, 30,000 min− 1 (VDI 12, VWR). NAD concentration was performed 
using a bioluminescent assay (NAD/NADH Glo-™, Promega). Kit re-
agents were prepared according to the manufacturer’s instructions. 
NAD-standards were prepared in HBSS from a 2 mM NAD stock (no. 
N8285, Sigma-Aldrich). Either 50 μl of sample (100,000 cells/well for 
retina) or NAD standard were combined with 50 μl of reagent in a 96- 
well plate (Nunc™ F96 MicroWell™ White Polystyrene plate, Thermo-
Fisher Scientific). Luminescence was recorded at approx. 1 h from initial 
mixing (plate shake in machine) to give sufficient time for the reaction 
to occur and remain stable. Luminescent intensity was converted to NAD 
concentration using the NAD standard curve. In order to assess how 
quickly nicotinamide could be utilized by cells to increase NAD con-
centration NAD assays were performed on treated retina, optic nerve, 
and brain cortex. C57BL/6J mice (n = 4 mice) were euthanized by 
cervical dislocation and eyes and optic nerve dissected as above with the 
exceptions that retinas from left and right eyes were pooled to form a 
single sample (giving a concentration after processing of 1.4 million 
cells/ml) and where optic nerves were cut to 2 mm. Whole cortex was 
removed, separated by hemisphere, transferred to 800 μl of dispase and 
processed as for the retina above to achieve a concentration of 2 million 
cells/ml. From each sample (retina, optic nerve and cortex) 4 aliquots of 
cell homogenate were taken for incubation with NAM (0 mM, 0.1 mM, 
10 mM) for either 0, 2, 4, or 6 h. NAM was added to the correct con-
centration to the samples so that all incubation times would complete at 
the same time point. The bioluminescent assay was then conducted as 
above. 
2.14. Generation and characterization of MitoV mouse 
MitoV mice were an independent founder (substrain 1819) in the 
generation of transgenic mice described by Misgeld et al. and as detailed 
by Burgess and Fuerst [24,25]. YFP is expressed under a rat Eno2 pro-
moter (neuron specific) and localized to mitochondria via a Cox8a 
gene-targeting signal fused to the YFP N-terminus. Mice are on a 
C57BL/6J background. We selected this line based on specificity of inner 
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retinal expression (designated MitoV for visual tissue). Four week old 
mice were euthanized by cervical dislocation, eyes were enucleated and 
fixed in PFA for 1 h, before performing immunofluorescent labelling as 
described above with anti-GFP and anti-RBPMS antibodies. Brains were 
fixed in PFA and processed for whole brain cryo-sectioning as described 
above. 
2.15. Super-resolution fluorescent imaging of mitochondria and 
morphological analysis 
Super-resolution fluorescent images of mitochondria were captured 
using Airyscan imaging on a Zeiss LSM800-Airy (63X, 1.3X optical 
zoom, 66.76 × 66.76 μm images, 35 nm/pixel, z-stacks with 15 nm slice 
thickness). For MitoV mouse tissue, images were acquired of Alexa Fluor 
488 conjugated secondary antibodies targeting anti-GFP primary anti-
body to limit loss of signal from potential YFP bleaching. To allow for 
practical acquisition times, only the mitochondrial channel was imaged; 
DAPI nuclear stain and RBPMS labelling in the same image window were 
captured as snapshots only for reference purposes. Secondary antibody 
only controls were used for all experiments to set suitable imaging pa-
rameters. Retina axotomy explant was performed on MitoV retinas, with 
4 retinas maintained for 0 DEV (control), 4 retinas for 0.5 DEV, and 4 
retinas for 0.5 DEV with NAM supplemented media (500 mM). Retinas 
were imaged as flat mounts, with 4 images collected at 1000 μm ec-
centricity from the optic nerve head superiorly, nasally, inferiorly, and 
temporally. Images were captured as z-stacks from the NFL to the lower 
boundary of the GCL. The intravitreal rotenone injection model was 
performed with 9 DMSO (vehicle only) injected retinas, 4 Rotenone (10 
mM) injected retinas and 7 Rotenone injected retinas where animals 
were pre-treated with NAM (500 mg/kg/d) for 1 week prior to injection 
and maintained for the duration of the experiment. Eyes were enucle-
ated 24 h after injection, fixed in PFA and processed for cryo-sectioning 
as described above. 20 m cryosections were cut and immunofluorescent 
labelling performed using Alexa Fluor 488 conjugated secondary anti-
bodies targeting anti-GFP primary antibody. Airyscan images were ac-
quired of central retina ~500 μm later to the optic nerve head, 
encompassing the NFL, GCL and inner plexiform layer (IPL). The IPL was 
cropped for analysis. In rat tissue, 5 NT eyes (from 3 rats), 6 OHT eyes 
(from 4 rats) and 4 OHT-NAM (from 4 rats, pre-treatment with 800 mg/ 
kg/d NAM) were collected 14 days after OHT induction and processed 
for cryo-sectioning as described above. Alexa Fluor 568 conjugated 
secondary antibodies targeting anti-TOMM20 primary antibodies was 
imaged. Image capture and analysis followed the same protocol as for 
rotenone injected eyes. IPL and GCL/NFL crops were analyzed sepa-
rately. In all three models, mitochondria were reconstructed in 3D using 
Imaris software (version 9.3.1). Volume reconstructions were performed 
using the surfaces tool and individual volume and surface area were 
calculated. Volumes <125 voxels were filtered and removed from sub-
sequent analysis to reduce noise. 
2.16. Live-imaging of mitochondria 
RGC cultures were established according as previously described 
([26], modified from [27]). Six to seven day old C57BL/6J pups were 
euthanized and retinas dissected (n = 16–18 per panning procedure, 3X 
repeats). Retinas were dissociated in DPBS (Thermofisher, UK) by for-
ceps within 35 min at room temperature under 4X dissecting microscope 
followed by gentle trituration. RGCs were purified using two-step 
immune-panning on two Lectin coated negative panning plates (Ban-
deiraea simplicifolia, BSL-1; Vector Laboratories Ltd.) and a Thy1.2 
antibody coated positive plate (Serotec MCA02R, Bio-Rad), over 45 min 
at room temperature (25 ◦C). RGCs were seeded at a density of 50,000 
cells per well (24 well plate; Nunc, Thermofisher) on Poly-D-lysine and 
laminin coated glass coverslips (Sigma-Aldrich, R&D Systems, and 
Academy Science Limited, respectively). RGCs were cultured in 
serum-free growth medium (37 ◦C, 10% CO2) for 10 wells as previously 
described and treated with NAM dissolved in the media at concentra-
tions of 0, 50, 100, 500, and 1000 μM at day 7 post seeding. At eight days 
post seeding, mitochondria were stained with MitoTracker Red CMXRos 
(Molecular Probes, Invitrogen) for 30 min at 37 ◦C. Using a Zeiss LSM 
880 confocal microscope (63X oil immersion lens, 0.132 μm/px) 
time-lapse imaging was performed in order to record mitochondrial 
movement. Images were captured every 5 s for 10 min. Mitochondria 
were classified as either stationary or moving over the 10 min recording 
based on a total 5 μm distance threshold. Mitochondrial length (long 
axis), and number of mitochondria (total, motile, stationary) in the 
entire length of neurites in each group was measured in the first frame 
(Fiji) and Kymographs of mitochondrial movements were generated 
using the KymoAnlyzer plugin [28] for Fiji. Mitochondrial velocity was 
calculated as distance travelled on the kymograph x axis divided by 
length of the y axis (duration of movement). 
2.17. Extracellular acidification rate and oxygen consumption rate 
RGCs were purified from mice according to the methods previously 
described by Skytt et al. and Vohra et al. [29,30]. Culture media was a 
combination of Neurobasal A medium and DMEM, supplemented with 
glucose to reach a final concentration of 6 mM, and with pen-
icillin/streptomycine, sato, T3, B27, NAC, Trace elements B, biotin, 
CNTF, BDNF, forskolin, FGFB, and insulin as described in the references 
above. RGCs were cultured in a Seahorse 96-well cell culture microplate 
at a density corresponding to 450,000 cells/cm2. Glycolytic and mito-
chondrial respiratory function was measured using real-time assessment 
of, respectively, the extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR) with the Seahorse XFe96 Extracellular Flux 
Analyzer (Seahorse Biosciences-Agilent Technologies, USA) after one 
week. On the day prior to the assay, cells were pre-incubated 24 h before 
the analysis under the different experimental conditions: Control (0 μM 
nicotinamide (NAM)), 50 μM NAM, 500 μM NAM and 1000 μM NAM in 
culture media as above (no pyruvate, no glutamine) Prior to the assay, 
culture media was changed to CO2 calibrated Seahorse XF DMEM (un-
buffered, adjusted to pH 7.4, supplemented with glucose to reach a final 
concentration of 6 mM) and the cells were equilibrated for 15 min at 
37 ◦C in a CO2-free incubator. Time of calibration inside the seahorse 
instrument was set for further 15 min. Each OCR measurement cycle 
consisted of 3-min mix and 3-min measurement of the oxygen level, as 
well as ECR. The analysis of glycolytic and mitochondrial function was 
initiated by three baseline OCR measurement cycles. The pH of the re-
agents used to test mitochondrial function was adjusted to 7.4. The OCR 
and ECR were recorded and calculated by the Seahorse XFe96 software, 
Wave (Seahorse Biosciences-Agilent Technologies, USA). To normalize 
the data after the Seahorse analysis, the protein content for each well 
was measured using a BCA assay with BSA as standard. Measurements 
were acquired for 3–5 different cell batches per condition. 
2.18. Whole-cell patch-clamp electrophysiology 
C57BL/6J mice (12 weeks) were anesthetized with 2% isoflurane 
and cervically dislocated. Eyes were enucleated and placed into cutting 
solution consisting of (mM): 125 Choline-Cl, 2.5 KCl, 0.4 CaCl2, 6 MgCl2, 
1.25 NaH2PO4, 26 NaHCO3, 20 D-glucose, on ice and saturated with 95% 
O2 plus 5% CO2. The cornea was pierced with a 30 G needle and the 
retina dissected out. The retina was then incubated for 2 h at room 
temperature in Ames medium (Sigma Aldrich; AUS) and 1.9g sodium 
bicarbonate (Sigma Aldrich; AUS) with either 1 mM, 10 mM or 100 mM, 
or 250 mM NAM (Sigma Aldrich; AUS) or control solution saturated with 
95% O2 and 5% CO2. Retina were transferred to a submerged recording 
chamber on an upright microscope (Slicescope Pro 1000; Scientifica, 
UK). For all recordings, retina were perfused (2 ml/min) with Ames 
medium saturated with 95% O2 plus 5% CO2 at 24 ◦C, containing either 
1 mM, 10 mM, 100 mM or 250 mM NAM or control (0 mM) solution as 
per the previous incubation step. The center of the retina was located 
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using infrared-oblique illumination microscopy with a 4x air objective 
(Olympus, Japan) and a CCD camera (IEEE 1394; Foculus, Germany) 
and retinal ganglion cells visualized using a 40 × water-immersion 
objective (Olympus, Japan). Retinal ganglion cells with large cell bodies 
were chosen and their identity confirmed by the presence of AP firing 
and post-hoc biocytin immunohistochemistry (detailed below). Patch 
pipettes (6–9 MΩ; GC150F-7.5; Harvard Instruments; USA) were pulled 
using a Flaming/brown micropipette puller (Model P-1000; Sutter in-
struments, USA) and filled with solution containing (mM): 115 K-glu-
conate, 5 KCl, 5 EGTA, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP, and 7 
phosphocreatine (pH 7.3). Once whole-cell configuration was obtained, 
a holding current was injected to maintain a holding potential of 
approximately − 60 mV. Cells were excluded if a holding current greater 
than − 100 pA was required to achieve a membrane potential of − 60 mV. 
Patch clamp recordings were performed using a PatchStar microma-
nipulator (Scientifica, UK) and Axon Multiclamp 700B patch-clamp 
amplifier (MDS, USA). Current clamp data were acquired using 
pClamp software (v10; MDS, USA) with a sampling rate of 100 kHz and 
low pass Bessel filtered at 10 kHz (Digidata 1440a; Axon). Action po-
tential firing was recorded using an episodic protocol with the following 
current steps (0–200 pA in 10 pA steps, 400 ms duration, 5s inter sweep 
interval). 
2.19. Analysis of action potential firing 
Data were analyzed using AxoGraph X software (Berkeley, CA, USA). 
Action potentials were detected using an amplitude threshold of 50 mV 
relative to pre-event baseline. Input-output curves were calculated by 
determining the number of action potentials generated for each injected 
current step. All action potential kinetics were analyzed for the first 
action potential at rheobase current, defined as the minimum current 
injection required to generate an action potential. Action potential 
threshold was defined as 30 mV/s. Action potential amplitude was 
calculated relative to pre-event baseline. Action potential half-width 
was calculated at 50% of maximal action potential amplitude. The ac-
tion potential rise-time was calculated as the time between 20% and 
80% of the maximal action potential amplitude. 
2.20. Biocytin immunohistochemistry and morphological analysis 
Following the completion of recordings, retina were removed, fixed 
in 4% paraformaldehyde in 1 M phosphate buffer overnight at 4 ◦C then 
washed three times for 5 min in 1 M phosphate buffer. Retina were 
incubated overnight at room temperature in Alexa Fluor 488 streptavi-
din (S11223, ThermoFisher Scientific, USA). Retina were mounted using 
ProLong Gold Antifade Mountant (P36930, ThermoFisher Scientific, 
USA) and z-stack images were acquired on a Zeiss LSM 780 confocal 
microscope (Zeiss, Germany). Whole dendritic arbors were recon-
structed using Imaris as above. Sholl analysis and dendritic field area 
measurements were generated in Imaris and soma diameter was 
measured on z-projections in Fiji (using the longest axis). 
2.21. Statistical analysis 
All statistical analysis was performed in R. Data were tested for 
normality with a Shapiro Wilk test. Normally distributed data were 
analyzed by Student’s t-test or ANOVA (with Tukey’s HSD). Non- 
normally distributed data were transformed using squared transforms; 
data that remained non-normally distributed was analyzed by a Kruskal- 
Wallis test followed Dunn’s tests with Benjamini and Hochberg correc-
tion. Unless otherwise stated, * = P < 0.05, ** = P < 0.01, ***P < 0.001, 
NS = non-significant (P > 0.05). For box plots, the center hinge repre-
sents the mean with upper and lower hinges representing the first and 
third quartiles; whiskers represent 1.5 times the interquartile range. 
3. Results 
3.1. Nicotinamide confers retinal ganglion cell neuroprotection in a range 
of glaucoma-relevant contexts 
Nicotinamide is protective in a genetic mouse model (DBA/2J) that 
recapitulates features of a human pigmentary glaucoma and demon-
strates an age-related decline in retinal NAD [5]. To further determine 
how nicotinamide (NAM) protects retinal ganglion cells (RGCs), we 
induced RGC degeneration in two separate glaucoma relevant insults in 
the absence of an age related effect: elevated IOP and optic nerve 
degeneration induced by axotomy. We first confirmed the neuro-
protective effects of NAM in an inducible, acute rat model of glaucoma 
where the onset of high IOP is controlled and abrupt. Restriction of the 
anterior chamber drainage structures via magnetic microbead injection 
limits aqueous humor fluid outflow, producing significant ocular hy-
pertension (OHT; elevated intraocular pressure) which is sustained for 
two weeks (Fig. 1A). NAD was significantly reduced in the retina and 
optic nerve of OHT animals at 14 days post-induction (Fig. 1B) (i.e. 
IOP-dependent, not age-dependent NAD decline). In vivo imaging using 
optical coherence tomography (OCT) demonstrated loss of the neuro-
retinal rim (representing intra-retinal retinal ganglion cell axons; 
Fig. 1C). Rats pre-treated with NAM (200 mg/kg/d dietary, represen-
tative of 2 g/d for a 60 kg human [31]; with treatment continuing for the 
duration of OHT) did not demonstrate loss of the neuroretinal rim 
despite maintaining a similar IOP (Fig. 1C). OHT eyes demonstrated 
significant RGC loss as assessed by RBPMS + counting (an RGC specific 
marker in the retina, Fig. 1D). The average RGC nuclear diameter 
(RBPMS + DAPI nuclei) was also significantly decreased, suggesting that 
surviving cells were under considerable neurodegenerative stress 
(Fig. 1E) [32]. NAM treated OHT rats demonstrated significantly 
reduced RGC loss and nuclear shrinkage in a dose dependent manner 
(200, 400, or 800 mg/kg/d dietary, representative of 2, 4, or 8 g/d for a 
60 kg human [31]; Fig. 1E). These data support a neuroprotective role 
for NAM in the context of high IOP without an associated age-related 
NAD decline. 
We next tested NAM protection in an acute, axon-specific injury 
using a retinal explant model [12,13]. Enucleation severs RGC axons in 
the optic nerve, and explants maintained in culture ex vivo, demon-
strated a progressive RGC loss and nuclear shrinkage observed within 
12 h, with highly significant, reproducible RGC loss at 3 days ex vivo 
(Fig. 2A and B, Supplementary Fig. 1 A and B). This RGC loss and nu-
cleus shrinkage is robustly prevented by NAM-supplemented media at a 
range of doses. Using this explant model we assessed whether protection 
extended to RGC axons and dendrites. RGC axons within the retinal 
nerve fiber layer (RNFL) demonstrated a significant increase in the 
number of varicosities, a metric of neurite degeneration, by 3 days ex 
vivo, but with no change in average varicosity size (Fig. 2C and D, 
Supplementary Fig. 1C and D). These changes were not observed in NAM 
treated retina, even by 3 days ex vivo, demonstrating significant pro-
tection against severe acute axon degeneration (Fig. 2C and D). At 3 days 
ex vivo RGCs had significant dendritic atrophy compared to control 
retina (0 days ex vivo), with reduced complexity (as assessed by Sholl 
analysis), total dendritic length, and dendritic field area. NAM treatment 
was highly effective, preserving dendritic morphology (Fig. 2E and F). 
Dendritic varicosities were significantly increased in density as a func-
tion of dendrite length and dendritic field area, indicating dystrophy and 
degeneration of dendrites. NAM at a range of doses prevented these 
changes (Fig. 2E and F). These data support previous findings on the 
protective effects of NAM, and extend its known effects to encompass 
neuroprotection across RGC compartments within the retina in addi-
tional animal models. 
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3.2. Nicotinamide alters metabolic profiles in normal, non-diseased 
retinal ganglion cells 
Given the importance of NAD in a wide array of metabolic processes 
and the potential of NAM as an interventional and prophylactic treat-
ment in human glaucoma, we sought to determine whether NAM 
treatment alters RGC metabolic profiles under normal physiological 
conditions. We optimized a low molecular weight mass spectrometry 
platform to assess 73 essential low molecular weight metabolites across 
the RGC trajectory in normotensive rats (NT; normal IOP, no disease). 
We used bulk tissue (rat retina, optic nerve, superior colliculus (SC; the 
major RGC terminal in the rodent)) to avoid metabolic changes induced 
by cell sorting or tissue processing protocols. These data provide a novel 
metabolome across RGC compartments; dendrites, soma, and 
Fig. 1. Nicotinamide provides neuroprotection in a rat bead model of ocular hypertension. (A) Ocular hypertension (OHT; n = 26 eyes) induced by the 
magnetic bead injection lead to a significant increase in IOP over control (NT; n = 20 eyes), which persisted for 14 days (greater than 2 standard deviations of NT, 
blue line). Nicotinamide (NAM) treatment in OHT animals (200, 400, 800 mg/kg/d; n = 10, 12, and 24 eyes respectively) did not lower IOP (as assessed by area 
under the IOP curve). (B) Following 14 days of sustained OHT, NAD was significantly reduced in both the retina (n = 6) and optic nerve (n = 6) as measured by 
luminometry-based assays. (C) In vivo OCT imaging demonstrated significant loss of neuroretinal rim following 14 days OHT (n = 7 eyes) compared to NT eyes (n =
9), which was absent in NAM treated rats (n = 8 eyes; measured as the cup depth relative to retinal thickness; loss denoted by white * on example image). (D) RBPMS 
(RGC specific) and DAPI labelling of the retina demonstrated a dose dependent, significant neuroprotection against RGC loss and RGC nuclear shrinkage at day 14 (E; 
n = 10 NT retinas, 10 OHT, 9 OHT-NAM (200 mg/kg/d), 12 OHT-NAM (400 mg/kg/d), and 12 OHT-NAM (800 mg/kg/d)).Scale bar = 100 μm in C, 20 μm in D. **P 
< 0.01, ***P < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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Fig. 2. Nicotinamide protects against axonal and den-
dritic degeneration. (A) Retinal axotomy explant results 
in significant RGC death and nuclear shrinkage, at 3 days 
ex vivo (DEV) with robust protection provided by NAM 
treated media (B; n = six 0 DEV retinas, six 3 DEV un-
treated, six 3 DEV-NAM (100 mM), eleven 3 DEV-NAM 
(500 mM)). (C) β-tubulin labelling reveled a significant 
increase in axonal varicosities within the retinal nerve fiber 
layer at 3 DEV, which were robustly protected against by 
NAM (D; n = six 0 DEV retinas, six 3 DEV untreated, six 3 
DEV-NAM (100 mM), six 3 DEV-NAM (500 mM)). (E and 
F) At 3 DEV significant changes to the complexity of the 
dendritic arbor were apparent (E; example RGCs labelled 
by DiOlistics). At 3 DEV there was a loss of branch density 
(reduction in Sholl AUC), a reduction in dendritic length 
and field area. NAM treated media provided significant 
protection against these neurodegenerative features (n =
75 RGCs from ten 0 DEV retinas, 46 RGCs from twelve 3 
DEV untreated, 53 RGCs from twelve 3 DEV-NAM (100 
mM), 62 RGCs from twelve 3 DEV-NAM (500 mM)). At 3 
DEV dendrites display an increased density of varicosities, 
which was protected against by NAM (F; n = 55 RGCs from 
0 DEV retinas, 23 RGCs from 3 DEV untreated, 38 RGCs 
from 3 DEV-NAM (100 mM), 32 RGCs from 3 DEV-NAM 
(500 mM)). Scale bar = 20 μm in A, 50 μm in C and E. 
*P < 0.05, **P < 0.01, ***P < 0.001.   
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unmyelinated axons (retina), myelinated axons (optic nerve), and ter-
minal arbors (SC) (Supplementary Dataset 1 and 2; raw and normalized 
data). The normal rat metabolome varies significantly by these selected 
regions, with all 73 metabolites differentially abundant across tissues. 
Unsupervised hierarchical clustering (HC) separated samples into 
discrete groups that matched the different tissues, confirming globally 
distinct metabolic profiles (Supplementary Fig. 2A). Metabolites were 
most highly abundant in the optic nerve, followed by the SC and retina 
respectively. Correlation of all individual metabolites for all samples 
demonstrated that the SC had the highest intra-tissue correlation 
(Fig. 3A). In order to identify distinct metabolic signatures of the 
discrete tissues we used principle component analysis (PCA). Unsuper-
vised PCA separated samples into discrete tissue groups supporting the 
HC data with PC1 describing the vast majority of variation (95.3%; 
Fig. 3B). Creatine, hypotaurine, 2-aminobutyric acid, glycer-
ophosphocholine, and cysteine were the highest contributing loading 
factors in to PC1 demonstrating that relative abundance remained the 
largest determinant of tissue type even after scaling to reduce its effects 
(Supplementary Fig. 2B and C). We specifically queried how NAD, 
NADH, and NAM vary across these tissues. NAD was higher in retina and 
optic nerve than in the SC, but NADH was much more abundant in the 
optic nerve. This results in a lower NAD:NADH ratio in the optic nerve. 
NAM was relatively low in the retina compared to both the optic nerve 
and SC (Fig. 3C). 
NT rats treated with NAM 10 days prior to metabolomic analysis 
demonstrated a small but statistically significant reduced IOP of − 1.2 
mmHg (the physiological impact of which is likely to be limited) 
(Fig. 4A). (It is important to note that NAM treatment did not affect IOP 
in the context of OHT; Fig. 1A.) HC of individual samples demonstrated 
that NT-NAM treated retina were largely similar to normal NT retina, 
but there was a clear distinction in metabolic profile in the optic nerve 
and SC (Fig. 4B). PCA demonstrated that NAM induced changes were not 
sufficient to drive group distinction (Fig. 4B). NAM treatment resulted in 
9 changed metabolites (11%) in the retina, 24 in the optic nerve (30%), 
and 5 in the SC (6%) (Fig. 4C–F, Supplementary Dataset 3). Increased 
NAD, NADH, and threonine were common to all tissues, with glyceric 
acid also increased in both retina and optic nerve (Fig. 4G, Supple-
mentary Fig. 3). These metabolites alone were sufficient to distinguish 
NT and NT-NAM samples by HC (Fig. 4G). NAM was only increased in 
the optic nerve, suggesting that conversion to NAD may be saturated in 
the optic nerve at this dose (Supplementary Fig. 3). The NAD:NADH 
ratio was only significantly altered in the optic nerve (40% increase), as 
NAD was increased to a greater proportion than NADH (~2.4 fold 
compared to ~1.7 fold), suggesting a larger pool of free NAD (Supple-
mentary Fig. 3). Pathways analysis revealed that NAM induced changes 
are predicted to significantly impact nicotinate and nicotinamide 
metabolism across the retina and optic nerve (Fig. 4H, Supplementary 
Dataset 4). Arginine biosynthesis is predicted to be affected in the retina, 
Fig. 3. Metabolic profiles of retinal ganglion cell related tissues. (A) Seventy three low molecular weight metabolites could be reliably detected in retina (n = 8), 
optic nerve (n = 8) and superior colliculus (SC; n = 8 hemispheres) of Brown Norway rats. Within tissue correlation of metabolites is demonstrated by a circus plot 
with linkers between metabolites. The number of significantly correlated metabolites is shown as a bar graph in the outer circle. The SC (pink) showed the greatest 
degree of within tissue correlation of metabolites. (B) Tissue differences were explored by principle component analysis (PCA) which revealed a clear distinction of 
tissues predominantly along one component (PC1). (C) NAD and related metabolites NADH and nicotinamide were compared between tissues. The optic nerve was 
most abundant in NAD, NADH, and nicotinamide but had the lowest NAD:NADH ratio, whilst the retina was comparatively low in nicotinamide, and the SC 
comparatively low in NAD and NADH. **P < 0.01, ***P < 0.001, NS P > 0.05. (For interpretation of the references to color in this figure legend, the reader is referred 
to the Web version of this article.) 
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Fig. 4. Nicotinamide alters metabolic profile of retinal ganglion cell related tissues. (A) High dose nicotinamide supplementation resulted in small significant 
decrease in IOP on average in NT eyes (n = 60 NT eyes, 40 NT-NAM (800 mg/kg/d) eyes). (B) BN rats were either untreated (NT) or maintained on NAM for 1 week 
(NT-NAM, 800 mg/kg/d) before metabolomics analysis of tissue. Unsupervised hierarchical clustering (HC) showed no clear distinction between NAM treated and 
untreated NT retina metabolic profiles (n = 8 NT retina, 8 NT-NAM), but clear separation in the optic nerve (n = 8 NT optic nerves, 8 NT-NAM) and superior 
colliculus (n = 8 NT SC hemispheres, 8 NT-NAM; all scaled where red = high correlation, blue = low correlation). Principle components analysis (PCA) showed little 
discriminating power indicating limited large scale NAM induced changes (NT = black, NT-NAM = red). (C) Comparison of NT and NT-NAM treated tissue revealed a 
number of significantly changed metabolites in D retina, E optic nerve, and F) superior colliculus (FDR < 0.05; red = increased in NT-NAM, blue = decreased), with 
the optic nerve the most changed. (G) Comparison of significantly changed metabolites across tissues revealed NAD, NADH, threonine, and glyceric acid (later in 
retina and optic nerve only) to be commonly increased (Euler plot showing total changed metabolites, with the number of common changed metabolites between 
tissues denoted in red). (G) HC dendograms and heatmaps (where red = highest value, blue = lowest value by row) demonstrate the clear difference in these 
metabolites between NAM treated and untreated retina, optic nerve ad superior colliculus. (H) Pathways analysis (KEGG) demonstrated that the changed metabolites 
(in D-F) resulted in minimal pathway changes of significant impact in the retina, and none in the superior colliculus. In the optic nerve, changes were predicted 
predominantly to NAD and related metabolite pathways. Pathways are highlighted red where FDR <0.05, and annotated when in conjunction with high impact (i.e. 
predicted knock-on effects to the pathway); size denotes the number of metabolites within the pathway (scale adjacent). **P < 0.01. (For interpretation of the 
references to color in this figure legend, the reader is referred to the Web version of this article.) 
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and phenylalanine, tyrosine and tryptophan biosynthesis, taurine and 
hypotaurine metabolism, alanine, aspartate and glutamate metabolism, 
D-glutamine and D-glutamate metabolism, and glycine, serine and thre-
onine metabolism are predicted to be altered in the optic nerve. In these 
pathways, significant impact was attributed predominantly to NAM and 
NAD or amino acids L-threonine, L-glutamate, L-aspartate, and phenyl-
alanine. There were no predicted pathway changes in SC dataset 
(Fig. 4H). When cultured in NAM, dissociated neurons from retina, optic 
nerve, and cortex produce increased NAD over untreated cells demon-
strating the ability to rapidly and directly metabolize NAM to NAD 
without the need for first pass metabolism (Fig. 5). 
3.3. Nicotinamide protects against metabolic disruption following ocular 
hypertension 
In order to determine the NAD and metabolic changes that may 
precede RGC death we performed metabolomics following 3 days of 
OHT, a time point at which IOP is high but no detectable RGC loss has 
occurred [11]. The retinal metabolome is significantly altered at this 3 
day time point. HC revealed heterogeneity across and within conditions, 
but with a division between samples such that NAM treated eyes were 
largely grouped and distinguished (Fig. 6A). In the retina OHT led to 25 
changed metabolites relative to NT controls (24 increased, 1 decreased). 
Notable changes were increased alpha-ketoglutaric acid, homocysteine, 
threonine, NAD, and glycerophosphocholine, while creatinine was the 
sole reduced metabolite (Fig. 6B). Comparison of OHT-NAM treated 
retinas to NT-NAM (thus excluding normal NAM induced changes) 
revealed that NAM treatment completely prevented any OHT induced 
metabolite changes (Fig. 6B). NAD remained high in OHT-NAM retinas 
(Supplementary Fig. 4A). Pathway analysis predicted changes to 
alanine, aspartate and glutamate metabolism, D-glutamine ad D-gluta-
mate metabolism, arginine biosynthesis, glyoxylate and dicarboxylate 
metabolism, and histidine metabolism (Fig. 6C). 
In the optic nerve, HC revealed discrete untreated and NAM groups 
(Fig. 6D). No metabolites were significantly changed in OHT relative to 
NT (Fig. 6E). In OHT-NAM, 24 metabolites were significantly lower than 
in NT-NAM. Comparison of OHT-NAM to untreated OHT and NT 
demonstrated only 2 and 4 changed metabolites respectively (Fig. 6F). 
Collectively, these data suggest that the NAM induced metabolic profile 
change exhibited in normal tissue is lost during OHT. Comparison of 
NAM changes in NT (NT vs. NT-NAM) and OHT (NT-NAM vs. OHT-NAM) 
optic nerve demonstrated 16 commonly changed metabolites that reflect 
NAM specific changes (Fig. 6G). HC using only these 16 metabolites was 
sufficient to separate individual NAM treated groups from untreated 
groups. Comparison of these changed metabolites relative to NT 
demonstrated marked increases in NT-NAM only, with OHT-NAM 
retuned to NT levels across all metabolites (with the exception of NAD 
and threonine) (Fig. 6G). Crucially, NAD, NADH, and NAM remained 
higher in OHT-NAM optic nerves than in untreated OHT optic nerves 
(Supplementary Fig. 4B). As high NAD is axon protective [33], then this 
suggests that there is likely to be a longer term neuroprotection to the 
optic nerve afforded by NAM. However, this will need to be definitively 
tested at later disease time points than those explored here. 
In the SC, NAM treated conditions were clearly distinguished by HC 
(Fig. 6H). During OHT 6 metabolites declined relative to NT controls, of 
which 5 of these changes were prevented in OHT-NAM (Fig. 6I). NAM 
treatment in OHT was sufficient to replete NAD in the SC, with a 
diminished increase over normal NT levels relative to NT-NAM (Sup-
plementary Fig. 4C). The small number of metabolite changes in the SC 
were insufficient to drive any predicted pathways changes. 
Comparison of changes in OHT across tissues revealed 5 commonly 
changed metabolites in the retina and SC (Fig. 6J). Of these, all were 
changed in opposing directions, demonstrating a concomitant increase 
in the retina and decrease in the SC. These data support a hypothesis in 
which RGC metabolism is altered early during glaucoma pathogenesis 
and that this is largely prevented or buffered by oral NAM 
administration. 
3.4. Nicotinamide protects retinal ganglion cells from metabolic crisis 
We have previously demonstrated dysregulated gene expression in 
RGCs across multiple metabolic pathways [5], including widespread 
upregulation of genes encoding oxidative phosphorylation (OXPHOS) 
proteins. Given that genetic changes coincide with mitochondrial cristae 
loss and increased cytochrome c, it can be hypothesized that these may 
reflect an upregulated transcriptional response in order to increase 
mitochondrial OXPHOS capacity. Gene expression in axotomized retina 
demonstrated a reduction in the mitochondrial-RNA:nuclear-RNA ratio 
suggesting a loss of mitochondrial capacity or a reduced number of 
mitochondria (Fig. 7A). We queried whether the ratio of ATP:ADP was 
reduced in OHT, which would indicate a switch towards glycolysis from 
OXPHOS, and how this may be affected by NAM treatment. No signifi-
cant changes in this ratio were detected in the retina or optic nerve at 3 
days in the rat OHT model. In the SC, the ATP:ADP ratio was signifi-
cantly reduced in OHT and this was prevented by NAM treatment 
(Fig. 7B). Since within condition variability was high, which may reflect 
mixed cell type-specific responses, we analyzed OXPHOS and glycolysis 
in purified mouse RGC cultures with NAM supplementation. Oxygen 
consumption rate was significantly increased in cells supplemented with 
50 and 500 μM NAM, with the effect diminished at higher concentra-
tions. No significant change in extracellular acidification rate was 
detected (Fig. 7C). These findings suggest that NAM supplementation 
increases RGC OXPHOS capacity. We therefore tested the ability of NAM 
to protect RGCs against OXPHOS inhibition using an intravitreal rote-
none model (Complex I inhibition which results in the rapid degenera-
tion of RGCs). Intravitreal injection of rotenone induced significant RGC 
death within 1 day, which was significantly reduced by NAM supple-
mentation (Fig. 7D and E). Thus, in the absence of axon degenerative 
stress, nicotinamide can provide a robust neuroprotection against 
mitochondrial stress. 
3.5. Nicotinamide increases mitochondrial size and motility 
Mitochondrial remodeling and/or loss is a common feature of 
neurodegenerative disease which may drive neuronal metabolic 
dysfunction. We directly assessed changes to mitochondrial morpho-
logical integrity after 14 days of OHT in the rat. TOMM20 labelled 
Fig. 5. Nicotinamide can be rapidly metabolized to NAD by retina, optic 
nerve, and brain tissue. Luminometry-based NAD assays on retina, optic 
nerve and cortex incubated with NAM showed that it can be converted to NAD 
within hours, increasing with increased exposure, suggesting an increase in the 
NAD pool (n = 4 retinal replicates where each is composed of 2 pooled retinas, 
for each time point a sample was taken from each replicate; n = 4 optic nerve 
replicates where 8 optic nerves were divided in to 1 mm segments to give 16 
independent samples for each time point; n = 4 cortex replicates where each 
replicates is a single cortex hemisphere and for each time point a sample was 
taken from each replicate). Optic nerve demonstrated the largest increase over 
control (untreated optic nerve) supporting the metabolomics observations. 
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mitochondria were imaged by super-resolution Airy confocal micro-
scopy and reconstructed (Fig. 8A). Mitochondrial volume and surface 
area were significantly reduced in the ganglion cell layer (GCL) and 
RNFL (comprising RGC soma and axons and other retinal neurons/glia) 
of OHT rats (Fig. 8B). NAM treatment partially protected from these 
mitochondrial degenerative changes. In OHT rats, mitochondrial vol-
ume and surface area were significantly increased in the IPL (comprising 
RGC dendrites and interneuron neuropil), and further increased in OHT- 
NAM treated rats (Fig. 8C). These different changes between retinal 
layers may be representative of the various cell types that make up these 
layers, their neuronal networks, and/or how they respond to OHT. To 
determine RGC specific mitochondrial responses to injury and NAM, we 
utilized a novel mitochondrial reporter mouse where YFP is expressed 
under a rat Eno2 promoter (neuron specific) and localized to mito-
chondria via a Cox8a gene-targeting signal fused to the YFP N-terminus 
(neuronal expression shown in Supplementary Fig. 5). In this strain 
(designated MitoV; for visual system tissue), YFP expression is RGC 
specific in the inner retina, allowing the assessment of mitochondria 
specifically in RGCs (with expression in a subset of bipolar cells and 
photoreceptor outer segments which can be optically dissected; Sup-
plementary Fig. 5A–C). We hypothesized that physical axonal damage 
and mitochondrial stress work in concert to drive vision loss in glau-
coma. To assess each of these in an isolated context, we induced RGC 
axotomy (uncoupling the RGC from the terminal visual thalami) or 
acute, severe mitochondrial dysfunction (intravitreal rotenone injec-
tion). Using the retinal explant model to induce an RGC specific injury, 
we assessed mitochondrial morphology in the GCL/RNFL (Fig. 9A). At 
12 h ex vivo mitochondrial volume and surface area were significantly 
increased. NAM supplementation of the media exaggerated the increase 
in mitochondrial volume and surface area (Fig. 9B). Intravitreal injec-
tion of rotenone resulted in a significant reduction of mitochondrial 
volume and surface area in the IPL at 1 day post injection. NAM 
Fig. 6. Nicotinamide prevents metabolic disruption. The metabolic profiles of BN rats following 3 days of OHT (prior to detectable neurodegeneration) were 
compared to NT controls, and the effects of pretreatment with NAM (800 mg/kg/d) explored (n = 8 retinas, optic nerves and superior colliculus hemispheres for each 
condition). (A) In the retina, unsupervised hierarchical clustering (HA) demonstrated that samples largely clustered based on exposure to NAM, but with hetero-
geneity across conditions (heatmap scaled where red = high correlation, blue = low correlation). (B) OHT induced a number of metabolic disturbances with a 
number of significantly increased metabolites (NT vs OHT; FDR < 0.05; red = increased in NT-NAM, blue = decreased; further shown in HA dendogram and 
heatmap; red = highest value, blue = lowest value by row); these changes were completely absent in NAM treated retinas (NT-NAM vs OHT-NAM; which controls for 
NAM specific effects). (C) Pathways analysis (KEGG) demonstrated a number of potentially effected pathways (pathways are highlighted red where FDR < 0.05, and 
annotated when in conjunction with high predicted impact, size denotes the number of metabolites within the pathway). (D) In the optic nerve, HA revealed clear 
distinction between NAM treated and untreated samples, irrespective of disease grouping. (E) No metabolites were significantly altered compared to NT following 3 
days of OHT (NT vs OHT). (F) While NT-NAM treated optic nerves demonstrated a number of significantly changed metabolites over NT nerves, these effects were 
lost under OHT as demonstrated by the reversal of a number of these changes (NT-NAM vs OHT-NAM) and the similar profiles of OHT-NAM optic nerves to both OHT 
and NT nerves (OHT vs OHT-NAM, NT vs OHT-NAM respectively). (G) Comparison of NT-NAM vs OHT-NAM changes against NT vs NT-NAM changes, demonstrated 
16 commonly changed metabolites (Euler plot showing total changed metabolites, with the number of common changed metabolites between comparisons denoted 
in red). HA of these metabolites separated individual NAM treated groups from controls, and plotting the mean abundance of these relative to NT control further 
highlights NAM specific changes that were reversed under OHT. (H) In the superior colliculus, HA largely distinguished individual groups, suggesting well defined 
metabolic profiles per condition. (I) In the SC, OHT resulted in a significant decrease of metabolites (NT vs OHT), which was prevented by NAM treatment (NT-NAM 
vs OHT-NAM). NAD in the SC was lower in OHT-NAM treated than NT-NAM treated (but remained above NT and OHT control levels; Supplementary Fig. 4). (J) 
Comparison of OHT changes relative to NT in the retina, ON and SC revealed that 5 metabolites were commonly changed, where increases in the retina were mirrored 
by decreases in the superior colliculus (Euler plot showing total changed metabolites, with the number of common changed metabolites denoted; for mean fold 
change plot, red = increase, blue = decrease). *P < 0.05, **P < 0.01, ***P < 0.001. (For interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
Fig. 7. Nicotinamide buffers against metabolic crisis. (A) RGC axotomy resulted in a decrease in mitochondrial: nuclear derived RNA (mtRNA:nuRNA; relative 
expression of mtCo2 and rps18) suggesting a loss of mitochondrial capacity or reduced numbers of mitochondria (n = five 0 days ex vivo (DEV) retinas, five 3 DEV). 
(B) The ratio of ATP:ADP was not significantly altered in the retina or optic nerve, but was reduced under OHT in the superior colliculus which could indicate a 
switch towards favoring glycolysis over oxidative phosphorylation (OXPHOS; n = 8 retina, optic nerve and superior colliculus hemispheres per condition). This was 
reversed under NAM treatment. (C) Oxygen consumption rate was significantly increased in cultured RGCs supplemented with 50 and 500 μM NAM, suggesting NAM 
increases OXPHOS capacity (n = 5 cultures with 0 μM NAM, 5 cultures with 50 μM NAM, 4 cultures with 500 μM NAM, and 4 cultures with 1000 μM NAM). 
Extracellular acidification rate did not change significantly (n = 3 cultures per condition). (D and E) Intravitreal injection of rotenone (causing rapid depletion of 
OXPHOS) caused significant loss of RGCs after 24 h, and pre-treatment with NAM provided significant protection against this loss (n = 8 retina per condition). Scale 
bar in D = 20 μm *P < 0.05, **P < 0.01, ***P < 0.001. 
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supplementation was unable to prevent these morphological changes 
even though NAM treatment was grossly neuroprotective (Fig. 9C and 
D). These data suggest that even across a range of insults, mitochondria 
increase or maintain their size when NAM is present. However, these 
changes may reflect the tissue culture conditions (e.g. Ca2+ buffering 
deficits or deviation from normoxia in the axotomy model) or the abrupt 
complete physiological loss of mitochondrial Complex I function (in the 
rotenone model) which are exaggerations of the intrinsic RGC injury 
responses during glaucoma pathogenesis. 
In order to differentiate NAM-induced and insult-induced mito-
chondrial changes we administered NAM in the diet of uninjured control 
MitoV mice for 1 week prior to fixation and imaging (Fig. 9E). RGC 
mitochondria in the GCL/RNFL increased in volume and surface area 
compared to untreated controls, suggesting that the increase in volume 
and surface area observed in the NAM treated injury paradigms were 
NAM specific responses (Fig. 9F). The presence of larger mitochondria 
prior to damage may therefore explain the maintenance of mitochon-
drial volume and surface area which was observed in the rat GCL/RNFL 
in NAM treated injuries and the exaggerated mitochondrial expansion 
seen in the rat IPL. In vivo imaging of MitoTracker labelled mitochondria 
in purified cultured RGCs (Fig. 10A) demonstrated an increase in 
mitochondrial size following NAM supplementation (24 h of pre- 
treatment) which was dose dependent (Fig. 10B). Mitochondria occu-
pied a greater proportion of neurite length (Fig. 10B). Live imaging, 
analyzed as kymographs (Fig. 10C), revealed a greater number of 
mitochondria and a striking increase in mitochondrial population 
mobility and velocity across NAM doses over untreated control 
(Fig. 10D). Total and stationary mitochondria displayed some variability 
with NAM dose (Fig. 10D). Larger, more mobile mitochondria may be 
indicative of increased mitochondrial fusion, with implications for 
increased OXPHOS capacity (as supported by the increased oxygen 
consumption rate) and maintenance of energy demands across the cell. 
3.6. Nicotinamide reduces retinal ganglion cell metabolic demands 
Since OXPHOS capacity and mitochondrial motility increased 
following NAM application, we questioned whether RGC electrical ac-
tivity was altered. Mouse retina were explanted and incubated with 
NAM for 2 h before patch clamping (example profiles displayed in 
Fig. 11A). At low NAM doses (1–10 mM) the action potential (AP) firing 
rate was slightly increased, with persistent firing at higher current in-
puts. Higher NAM doses (100–250 mM), in which we demonstrated 
neuroprotection in explant retina, demonstrated marked reduction in AP 
firing rates across current inputs (Fig. 11B). The firing rate (I/O rela-
tionship AUC), AP amplitude, and AP rise time were significantly 
reduced at higher NAM doses (Fig. 11C). Resting membrane potential, 
AP threshold, and rheobase were not affected by NAM suggesting 
integrity of the cell’s capacity to depolarize (Fig. 11D). These data 
suggest that the higher neuroprotective doses of NAM lower AP firing 
frequency in RGCs, without compromising their potential to fire, and 
thus may reduce RGC metabolic demands. Post-hoc morphological 
analysis of filled cells confirmed that all recorded cells were RGCs 
(presence of an axon). RGCs demonstrated broadly similar morphologies 
between conditions but with some variability (Supplementary Fig. 6). 
No cells were bi-stratified, and no cells had offset dendritic fields. This 
suggests that the observed changes to AP metrics are not predominantly 
the result of differing RGC types. RGCs within the group treated with 1 
mM NAM had significantly larger dendritic fields and somas compared 
to untreated RGCs (control) and as such may contain a different pro-
portion of RGC subtypes which could account for the observed differ-
ence in AP metrics in this group. 
4. Discussion 
The control of metabolic homeostasis is essential for normal physi-
ology as well as during stress- and disease-related episodes. To assess 
this in the context of ocular disease, we introduce a novel, small 
Fig. 8. Mitochondrial size changes following OHT. (A) Rat retina following 14 days of OHT (untreated (OHT, n = 6 retina) and NAM treated (800 mg/kg/d, OHT- 
NAM, n = 4 retina)) and NT control (n = 4 retina) tissue was cryo-sectioned, mitochondria labelled by anti-TOMM20, and imaged by Airy confocal scanning mi-
croscopy. The ganglion cell layer/retinal nerve fiber layer (GCL/RNFL) and inner plexiform layer (IPL) were analyzed separately (boundaries demarcated by white 
broken lines). (B) Mitochondrial volume and surface area were significantly reduced under OHT in the GCL/RNFL and this was mitigated by NAM (n = 535 
disconnected volumes in NT, 490 in OHT, 652 in OHT-NAM). (C) In the IPL mitochondrial volume and surface area increased under OHT, which was exaggerated 
under NAM treatment (n = 9729 disconnected volumes in NT, 8026 in OHT, 6413 in OHT-NAM). Zoom = inset of data points. Scale bar in A = 5 μm ***P < 0.001. 
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Fig. 9. Nicotinamide increases mitochondrial size. (A) Retinal axotomy culture of MitoV mice (RGC specific YFP labelled mitochondria in the inner retina) 
maintained for 0.5 days ex vivo (DEV) with or without NAM treated media (and controls fixed at point of euthanasia, 0 DEV) allowed imaging of RGC specific 
mitochondria in the GFL/RNFL by Airy confocal scanning microscopy following flat mounting (n = 4 retina for all conditions). (B) The mean mitochondrial volume 
and surface area were increased under axotomy, with a further increase in size under NAM treatment (n = 15,216 disconnected volumes in 0 DEV, 16,765 in 0.5 DEV, 
24,558 in 0.5 DEV + NAM). (C) The effects NAM at mitigating direct mitochondrial stress were investigated by intravitreal rotenone injection in MitoV mice (n = 9 
DMSO vehicle treated retina, 3 rotenone, 7 rotenone + NAM (500 mg/kg/d)). Tissue was cryo-sectioned and imaged by Airy confocal scanning microscopy and 
mitochondria within the IPL (boundary demarcated by cyan broken line). (D) Rotenone caused a reduction in mitochondrial volume relative to controls (DMSO 
vehicle) in the IPL. NAM had little effect is preventing this change (n = 15,380 disconnected volumes in DMSO vehicle treated retinas, 7987 in rotenone treated, 
10,418 in rotenone + NAM). These results demonstrate the heterogeneous nature of OHT insult on mitochondria that shares features with both direct RGC and direct 
mitochondrial stress. (E) In order to determine whether NAM increases mitochondrial size in uninjured retina, MitoV mice were maintained on a NAM diet (500 mg/ 
kg/d) for 1 week. Retina were fixed immediately after euthanasia and compared to untreated controls by Airy confocal imaging and reconstruction (n = 4 control 
retinas, 4 NAM supplemented). (F) NAM supplementation increased mean mitochondrial volume and surface area in RGCs, supporting observations of mitochondria 
under stress above (n = 15,216 disconnected volumes in control, 13,306 in NAM supplemented). Zoom = inset of data points. Scale bar = 5 μm in A, C, and E. **P <
0.01, ***P < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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molecular weight metabolome for the retina, optic nerve, and superior 
colliculus of the Brown Norway rat (Rattus norwegicus; the genetic 
standard for rat). We demonstrate that ocular hypertension causes early 
metabolic dysregulation that is largely prevented by nicotinamide 
treatment. These data advance the understanding of nicotinamide as a 
treatment for glaucoma by demonstrating substantial metabolic pro-
tection and robust mitigation of glaucoma-related insults across multiple 
retinal ganglion cell compartments. Elevated IOP is a major risk factor 
for glaucoma and is the most significant factor in many patients. We 
modelled glaucoma in this context with an acute, inducible IOP increase 
(ocular hypertension) and demonstrate that retinal and optic nerve NAD 
decline following ocular hypertension in the absence of an age-related 
effect on NAD homeostasis. It is important to note that significant 
retinal ganglion cell death has occurred at this time point (which may 
influence whole tissue NAD metabolism) and that at an earlier 3 day 
time point (high IOP, but no detectable retinal ganglion cell death [11]) 
NAD is yet to decline. In order to better understand the temporal nature 
of NAD decline and its role in glaucoma pathophysiology it will be 
important to investigate further disease time points to identify whether 
ocular hypertension related NAD decline precedes retinal ganglion cell 
death. Metabolomics revealed a number of significantly altered metab-
olites in the retina and superior colliculus, but with no detectable 
changes in the optic nerve at this early 3 day time point. Ocular hy-
pertension does not directly insult the superior colliculus. Therefore, any 
metabolic disruption to the superior colliculus must arise from retinal 
ganglion cell mediated processes, not limited to metabolic stress, but 
could include stresses such as loss of axoplasmic transport [11,34]. We 
cannot discount early neurodegenerative changes in the optic nerve on 
the basis of the absence of metabolic dysfunction (as detected using this 
metabolomics panel). However, the nicotinamide induced metabolic 
changes observed in normal optic nerve were lost in nicotinamide 
treated ocular hypertension optic nerves, which may imply subtle optic 
nerve metabolic changes during ocular hypertension. Crucially, NAD, 
NADH, and nicotinamide were all significantly elevated in ocular hy-
pertensive nicotinamide treated optic nerves. As NAD is crucial for axon 
protection [33], this suggests the potential for long term neuro-
protection of the optic nerve in glaucoma. 
Our previous experiments using the DBA/2J mouse demonstrated 
that increasing NAD via Nmnat1 gene therapy provides a robust neu-
roprotection. Over-expression of Nmnat1 provides this neuroprotection 
outside of the context of increased nicotinamide, but is additive when 
additional nicotinamide is added to the system [5]. It is therefore 
reasonable to hypothesize that directly increasing NAD provides retinal 
ganglion cell neuroprotection in this context, which is supported by the 
Fig. 10. Nicotinamide increases mitochondrial motility in RGCs. (A) In order to observe these NAM effects on mitochondria in vivo, RGC cultures were grown 
and exposed to NAM treated media for 24 h. MitoTracker labelled mitochondria were time-lapse imaged over 10 min (example images shown in A and as kymographs 
in C where the y axis = time (t) and the x axis = distance long the neurite (d)). Morphology was examined in the first frame and demonstrated that mitochondrial 
length was increased with increasing NAM concentration (B; n = 148 mitochondria in control, 154 in 50 μM NAM, 141 in 100 μM NAM, 140 in 500 μM NAM, 122 in 
1000 μM NAM; mitochondria from 8 neurites from 3 independent cultures for all conditions). Mitochondria occupied a greater percentage of neurite length in NAM 
exposed retina (B; n = 8 neurites from 3 independent cultures for all conditions), which was partially explained by an increase in observed mitochondria (D). Analysis 
of mitochondrial movements demonstrated a greater number of both mobile and stationary mitochondria (D; n = 3 independent cultures for all conditions). 
Mitochondrial velocity was significantly increased with NAM supplementation (D; n = 52 mitochondria in control, 356 in 50 μM NAM, 324 in 100 μM NAM, 249 in 
500 μM NAM, 292 in 1000 μM NAM; mitochondria from 3 independent cultures for all conditions). Since a greater number of stationary mitochondria were observed, 
this suggests that the increase in mitochondria numbers may be a factor of increase mitochondrial biogenesis. Scale bar = 10 μm in A and 20 μm in C. *P < 0.05, **P 
< 0.01, ***P < 0.001. 
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role of NAD in Wallerian degeneration [35]. However, there are other 
potential metabolic processes afforded by increasing nicotinamide levels 
that may confer, or partially confer, neuroprotection in addition to 
nicotinamide’s role in elevating NAD. In the nicotinamide treated tissue 
we cannot differentiate whether these metabolic changes are a conse-
quence of neuroprotection itself or are directly providing neuro-
protection. Following ocular hypertension, we observed a number of 
changed metabolites that may influence retinal ganglion cell neuro-
degeneration and neuroprotection. Creatine and creatinine were altered 
in the retina following ocular hypertension. Supporting this, creatine 
kinase (responsible for the conversion of creatine to phosphocreatine) 
expression is altered in retinal ganglion cells in the DBA/2J mouse 
model of glaucoma in response to elevated IOP. Ckb (creatine kinase, 
brain; coupled to glycolysis) is up-regulated and Ckmt1 (creatine kinase, 
mitochondrial 1; coupled to OXPHOS) is down-regulated [5]. The cre-
atine/phosphocreatine/creatine kinase system provides an important 
ATP buffer and energy shuttle system within tissues with high energy 
demand and fluctuation (since phosphocreatine cycling back to creatine 
generates ATP) [36]. Creatine supplementation is neuroprotective to 
retinal ganglion cells in cell culture but not in other in vivo in models of 
retinal excitotoxicity or acute ischemic injury [37]. We observed an 
increase in α-ketoglutaric acid, a key TCA cycle intermediate. α-keto-
glutarate dehydrogenase catalyzes the conversion of α-ketoglutarate to 
succinyl CoA (an NAD dependent reaction [38]). Reduction in the ac-
tivity of α-ketoglutarate dehydrogenase is well-established in many 
neurodegenerative diseases with a metabolic component [39]. We 
observed increased homocysteine in the retina following ocular hyper-
tension, which suggests potential neurotoxic metabolic changes in 
addition to energy disruption. Increased homocysteine has been 
described as a marker of a number of neurodegenerative diseases [40] 
and has been demonstrated to induce retinal ganglion cell death in vitro 
and in vivo (likely through an excitotoxicity mechanism) [41,42]. 
Further to this, glycerophosphocholine was also increased in ocular 
hypertension. Increased glycerophosphocholine is established as an in-
dicator of membrane integrity disruption in neurodegenerative disease 
[43] created by the breakdown of phosphatidylcholine by phospholi-
pase A2. Phospholipase A2 inhibitors or genetic knockout of phospholi-
pase A2 reduce ischemic neurodegeneration and attenuates Alzheimer’s 
disease in mouse models [44,45]. Supporting this, phospholipase A2 
activation has also been demonstrated in Alzheimer’s disease patients 
and post-mortem tissue [46,47]. Taken together, the neuroprotective 
role of nicotinamide may not be solely limited to its capacity to generate 
NAD, however these additional metabolites need to be definitively 
mechanistically tested. 
Nicotinamide treatment robustly protected against retinal ganglion 
cell damaging events. The maintenance of cellular NAD pools is critical 
for neuronal survival as it provides co-enzyme resources necessary for 
maintaining a variety of complex cellular functions including ATP pro-
duction, protein deacetylase activity, calcium homeostasis, conversion 
to NADPH, and the maintenance of gene expression and DNA repair [33, 
Fig. 11. Nicotinamide lowers action potential firing frequency in RGCs. (A) Mouse retina were explanted and incubated with NAM for 2hrs before patch 
clamping. Example traces for individual RGCs are shown for each treatment group (0 mV profile in grey, 50 mV profile in color, 100 mV profile in grey; total RGCs =
twelve control, eleven 1 mM NAM, ten 10 mM NAM, 17,100 mM NAM, eleven 250 mM NAM, from 3 retinas for each condition). (B) Action potential (AP) firing 
frequency was markedly reduced at higher doses of NAM (analogous to those that provide neuroprotection in the axotomy explant model). (C) The relationship of 
input current to output demonstrates a slight increase in AP firing at high current for low dose NAM (1 and 10 mM) with a significant reduction in firing across a large 
range of input currents for higher doses (100 and 250 mM). (C) AP amplitude was significantly reduced at the higher doses and AP rise-time was significantly 
increased. (D) NAM did not affect the resting membrane potential, threshold for achieving an AP or the Rheobase indicating that the potential/ability to fire was not 
altered. Reducing AP firing may lower the metabolic demands of RGCs thus contributing to its neuroprotective effects. *P < 0.05, **P < 0.01, ***P < 0.001. (For 
interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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48]. The presence of metabolic dysregulation and ATP depletion [5,49], 
calcium dysregulation [50], mitochondrial degeneration [4,5], and 
reactive oxygen species [51] all contribute to glaucoma pathogenesis, 
supporting a role for NAD as a critical regulator of neuronal health in 
glaucoma. Nicotinamide supplementation is, therefore, likely to confer 
multiple neuroprotective effects. These features are not unique to 
glaucoma and are common to other neurodegenerative diseases in 
which mitochondrial degeneration and metabolic dysfunction occur. 
Increasing NAD through multiple substrate avenues has protective ef-
fects in many of these diseases, including Alzheimer’s disease [52–55], 
Parkinson’s disease [56–59], other neurodegenerations [60,61], and 
other mitochondrial degenerative disorders [62,63]. Continued eluci-
dation of the mechanisms of Wallerian degeneration has further 
demonstrated the role of NAD in axon survival. NAD decreases in 
damaged axons [64], while expression of the WldS allele or viral over-
expression/modified localization of NMNATs are protective, restoring 
NAD levels [5,65–68]. Increased NAD appears to exhibit numerous 
functional local roles in this context, including providing sufficient 
substrate to mitigate local SARM1-dependent NAD consumption and 
protecting against nicotinamide mononucleotide (NMN) induced axon 
damage [69,70]. 
Metabolomic analysis confirmed that retina, optic nerve, and supe-
rior colliculus all demonstrated increased NAD following nicotinamide 
administration. Importantly, nicotinamide drove an increase in NAD in 
mature in vivo systems and in isolated neurons demonstrating that 
retinal neurons themselves are capable of utilizing nicotinamide without 
a requirement for first-pass metabolism or other structural chemical 
changes. Crucially, high dose nicotinamide caused minor changes to the 
normal metabolome, mostly influencing metabolites linked directly to 
NAD or increasing amino acids L-threonine, L-glutamate, L-aspartate, and 
phenylalanine with limited predicted pathway effects (i.e. low predicted 
impact on critical pathway nodes via KEGG analysis), suggesting that 
chronic nicotinamide treatment is unlikely to have substantial delete-
rious effects in visual system tissue metabolism in the long-term. This is 
important if nicotinamide is to be considered as a prophylactic in 
glaucoma patients where significant neurodegeneration is yet to occur. 
Hierarchical clustering revealed that tissues could be grouped based on 
the presence or absence of nicotinamide treatment over disease related 
changes. However, this was largely driven by large fold changes in a 
small number of metabolites in nicotinamide treatment as opposed to 
smaller fold changes in numerous metabolites in ocular hypertension. 
Metabolic stabilization and neuroprotection were achieved with rela-
tively short-term administration of nicotinamide (1 week prophylactic), 
and dissociated neurons were capable of mobilizing nicotinamide to 
NAD rapidly (within hours), demonstrating the short period required to 
achieve an increase in cellular NAD pools. These results support nico-
tinamide supplementation as a therapeutic strategy for neuroprotection 
in glaucoma with particular regard to its rapid mobilization to NAD in 
visual system tissues. While the rodent and human visual system share 
many common features, and NAD synthesis pathways are conserved, the 
metabolic consequences in humans could vary. As we focused on small 
molecular weight metabolites, the consequences to the whole metab-
olome remain unknown and further metabolomics and lipidomic studies 
in humans will be necessary especially within the context of clinical 
trials and long-term testing. To our knowledge, this is the first small 
molecular weight metabolome for these tissues which will provide a 
resource and may aid others in the identification of key metabolic 
changes related to visual pathologies. 
The extent to which the NAD increases were restricted to retinal 
ganglion cells is not known since the metabolomics data is derived from 
a mixed cell population which included retinal ganglion cell compart-
ments. The optic nerve, containing retinal ganglion cell axons, repre-
sents the most retinal ganglion cell enriched tissue based on the relative 
abundance of cell types, suggesting that retinal ganglion cells likely 
exhibit increased NAD following nicotinamide supplementation. 
Increasing NAD across multiple cell types, including glia which offer 
metabolic support to retinal ganglion cells, may enhance the neuro-
protective effect, yet this remains to be explored and is an exciting 
avenue for therapeutic research, especially in other neurodegenerative 
diseases in which compromised metabolic function is coupled with a 
neuroinflammatory components such as Alzheimer’s disease. Increasing 
NAD production by Nmnat1 gene therapy in retinal ganglion cells is 
neuroprotective and supports a hypothesis in which retinal ganglion cell 
specific strategies to increase NAD are neuroprotective [5]. Since the 
intracellular location of NAD is key to its neuroprotective effects [71] 
further studies examining this in retinal ganglion cells will aid in 
elucidating the mechanisms of neuroprotection. 
We identify mitochondrial protection and oxidative phosphorylation 
maintenance as potential routes to buffering retinal ganglion cells bio-
energetic insufficiency [72–74]. Nicotinamide treatment increased 
mitochondrial size in normal and disease conditions (ocular hyperten-
sion and axotomy, but not rotenone which specifically insults mito-
chondria). However, differing mitochondrial populations may reflect 
the health of the neuron rather than a direct nicotinamide effect on 
mitochondrial morphology. In cultured retinal ganglion cells, nicotin-
amide also increased basal mitochondrial size. Basal mitochondrial 
mobility was also significantly increased by nicotinamide. Typically, 
mitochondrial biogenesis occurs at the soma and anterograde axonal 
transport moves these new mitochondria down the axon, whereas 
retrograde axonal transport returns dysfunctional mitochondria to the 
soma for degradation [75]. Mitochondrial transport is ATP dependent 
and our data suggest a greater free ATP pool following nicotinamide 
administration. NAD levels are known to play an important regulatory 
role in mitochondrial biogenesis and degradation (in particular through 
SIRT1 and SIRT3 activity, which is increased by NAD [76–78]). Sup-
porting this, DBA/2J mice administered nicotinamide demonstrate an 
increase in Ppargc1 expression in retinal ganglion cells (encodes PGC-1α; 
a master regulator of mitochondrial biogenesis) [5]. 
Electrophysiological analysis of retinal ganglion cells demonstrated 
that nicotinamide treatment lowered action potential firing rates at the 
doses associated with neuroprotection. Further experiments will be 
necessary to corroborate these findings since we only sampled small 
numbers of retinal ganglion cells. Nicotinamide may elicit differing re-
sponses among the different retinal ganglion cell subtypes and using 
subtype reporter strains would allow isolation of specific subtypes of 
retinal ganglion cells. Alternatively, the use of multi-electrode arrays 
would facilitate the capture of hundreds of retinal ganglion cell re-
sponses which would deliver sufficient numbers so as to produce pop-
ulations with similar subtype compositions between comparisons. By 
washing in/out nicotinamide, the same cell could be followed over time, 
which would inform on the longevity and/or reversibility of the firing 
suppression. It should be noted that all of these methods are caveated as 
the preparation requires an axotomized retina. However, in other tissue 
preparations exogenous nicotinamide and NAD have demonstrated 
similar suppression and prolongation of action potential firing and ac-
tivity (neuronal and cardiac preparations) [79–83]. It is important to 
note that nicotinamide has been used therapeutically at high doses 
long-term in clinical preparations without noted incidences of visual or 
cognitive disturbances [9,74]. Pattern electroretinogram (ERG) is a 
retinal ganglion cell specific functional test, representing a global 
summation of retinal ganglion cell signals. Nicotinamide supplementa-
tion was sufficient to preserve pattern ERG under chronic glaucomatous 
pathology [5,84] and has demonstrated a recovery in visual function as 
assessed by ERG in human glaucoma patients [7]. These findings suggest 
that even if the changes in retinal ganglion cell activity identified by 
patch clamping were recapitulated in vivo, visual function would not be 
disturbed. A concomitant decrease in retinal ganglion cell metabolic 
demand through reduced action potential firing frequency could miti-
gate the effects of a retinal ganglion cell energy crisis. A reduced ener-
getic load on retinal ganglion cells may partially explain enhanced 
survival. 
These findings advocate furthering clinical trials for the use of 
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nicotinamide as a treatment for glaucoma. Nicotinamide has a long 
established clinical safety profile, with limited long-term side effects. 
Long-term clinical trials that include individuals with early glaucoma (in 
which cell loss is heterogeneous and a significant portion of healthy cells 
likely remain) will be essential in determining the potential for nico-
tinamide as a prophylactic treatment for glaucoma. However, longer- 
term treatment of nicotinamide in animals retain their importance, 
especially in non-human primates which closely recapitulate the human 
visual system. A number of disease preventative measures have been 
identified in animal models of glaucoma, which provide robust treat-
ment at early and mid-disease time points, but long-term neuro-
protective effects are not maintained or are yet to be demonstrated [18, 
85–88]. Animals were treated with high doses of nicotinamide that 
represent achievable scaled doses to humans (the lowest neuro-
protective dose here of 200 mg/kg/d in the rat representing 1.9 g/day in 
a 60 kg human [31]). While we did not test any extra-visual system 
effects of these doses, the safety of the doses suggested here, as well as 
doses up to 12 g/d, is already established [9]. Although some patients 
may find adherence to these doses difficult to achieve because of the 
necessary number of tablets (especially when taken in addition to other 
common medications typical of more elderly patients) and the regularity 
of dosing, doses in the 1–3 g/d range are likely to be suitable for many 
patients. Supporting this, 3 g/d (6 × 500 mg capsules) had a high 
tolerance and compliance in Hui et al. nicotinamide glaucoma clinical 
trial (94% adherence). 
5. Conclusions 
Collectively, our data suggest that nicotinamide given as an early 
intervention or as a prophylactic treatment produces minimal short- 
term changes to healthy, non-disease visual system tissue with no 
observed deleterious effects to normal retinal ganglion cells. Nicotin-
amide buffers against metabolic and bioenergetic insufficiency to pro-
vide a potent neuroprotection against a variety of glaucoma-related 
stresses. The doses used here are realistic for human treatment regimens 
and support further clinical trials for glaucoma as well as potentially a 
range of metabolic and ophthalmic diseases. 
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